ロード中...
4CPS-099 Nivolumab: clinical experience in a tertiary hospital
BACKGROUND: Nivolumab is a human immunoglobulin G4 monoclonal antibody, which binds to the programmed death-1 receptor and blocks its interaction with PD-L1 and PD-L2. It is approved for melanoma, renal, urhotelial, non-small cell lung cancer (NSCLC) and other types of cancer. PURPOSE: To evaluate t...
保存先:
| 出版年: | Eur J Hosp Pharm |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Group
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535528/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.190 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|